Table 1 Baseline Characteristics and Predictors of 30-Day Readmission in Patients Receiving Outpatient Parenteral Antimicrobial Therapy
Parameter | Total (N = 200) | Readmitted (n = 42) | Not Readmitted (n = 158) | Univariate analysis p-value |
|---|---|---|---|---|
Age (years) [median (range)] | 60 (20–95) | 66.5 (29–95) | 59 (20–92) | < 0.01 |
Male gender | 131 (65.5) | 28 (66.7) | 103 (65.2) | > 0.20 |
Weight (kg) [median (range)] | 79 (31–176) | 75.5 (52–147) | 80.5 (31–178) | 0.08 |
Assigned primary care provider | 131 (65.5) | 27 (64.3) | 104 (65.8) | > 0.20 |
Insurance | > 0.20 | |||
Government-funded | 140 (70) | 29 (69.0) | 111 (70.3) | |
Private | 56 (28) | 12 (28.6) | 44 (27.8) | |
Self-pay | 4 (2) | 1 (2.4) | 3 (1.9) | |
Charlson Comorbidity Index [median (IQR)] | 2 (1–3) | 2 (1–3) | 2 (1–3) | > 0.20 |
Any diabetes | 82 (41) | 21 (50) | 61 (38.6) | 0.18 |
Immunosuppression | 36 (18) | 8 (19) | 28 (17.7) | > 0.20 |
Connective tissue disease | 35 (17.5) | 8 (19) | 27 (17.1) | > 0.20 |
Chronic pulmonary disease | 34 (17) | 5 (11.9) | 29 (18.4) | > 0.20 |
Peripheral vascular disease | 31 (15.5) | 6 (14.3) | 25 (15.8) | > 0.20 |
CVA/dementia | 20 (10) | 7 (16.7) | 13 (8.2) | 0.14 |
Mild liver disease | 15 (7.5) | 5 (11.9) | 10 (6.3) | > 0.20 |
Congestive heart failure | 13 (6.5) | 5 (11.9) | 8 (5.1) | 0.15 |
Moderate/severe renal disease | 8 (4) | 1 (2.4) | 7 (4.4) | > 0.20 |
Hemiplegia | 7 (3.5) | 0 (0) | 7 (4.4) | > 0.20 |
Myocardial infarction | 5 (2.5) | 0 (0) | 5 (3.2) | > 0.20 |
Peptic ulcer disease | 2 (1) | 1 (2.4) | 1 (0.6) | > 0.20 |
Moderate/severe liver disease | 2 (1) | 1 (2.4) | 1 (0.6) | > 0.20 |
Prior admission to MSBI within past 12 months | 103 (51.5) | 24 (57.1) | 79 (50) | > 0.20 |
Prior OPAT within past 12 months | 20 (10) | 4 (9.5) | 16 (10.1) | > 0.20 |
Hospital length-of stay [median (IQR)] | 9 (6–15) | 11.5 (7–15) | 9 (5–15) | 0.06 |
Inpatient service | > 0.20 | |||
Medicine | 138 (69) | 30 (71.4) | 108 (68.4) | |
Surgery | 62 (31) | 12 (28.6) | 50 (31.6) | |
ID consult | 191 (95.5) | 40 (95.2) | 151 (95.6) | > 0.20 |
ID teaching service | 100 (52.4) | 24 (60) | 76 (50.3) | > 0.20 |
Private ID attending | 91 (47.6) | 16 (40) | 75 (49.7) | |
ICU admission | 48 (24) | 13 (31.0) | 35 (22.2) | > 0.20 |
Outpatient disposition/OPAT location | < 0.01 | |||
Home | 120 (60) | 16 (38.1) | 104 (65.8) | |
SNF/SAR | 80 (40) | 26 (61.9) | 54 (34.2) | |
Post-discharge follow up | > 0.20 | |||
ID follow up | 129 (64.5) | 27 (64.3) | 102 (64.6) | |
Non-ID follow up | 71 (35.5) | 15 (35.7) | 56 (35.4) | |
Prior history of MDR organisms | 25 (12.5) | 5 (11.9) | 20 (12.7) | > 0.20 |
ESBL | 10 (35.7) | 1 (20) | 9 (39.1) | > 0.20 |
MRSA | 15 (53.6) | 4 (80) | 11 (47.8) | |
VRE | 3 (10.7) | 0 (0) | 3 (13.0) | |
MDR organism isolated during admission | 43 (21.5) | 8 (19.0) | 35 (22.2) | > 0.20 |
ESBL | 17 (37.8) | 4 (50) | 13 (35.1) | > 0.20 |
MRSA | 23 (51.1) | 4 (50) | 19 (51.4) | |
VRE | 5 (11.1) | 0 (0) | 5 (13.5) | |
Indication for OPAT | ||||
Osteomyelitis/septic arthritis | 71 (35.5) | 18 (42.9) | 53 (33.5) | > 0.20 |
Skin and soft tissue infection | 47 (23.5) | 9 (21.4) | 38 (24.1) | > 0.20 |
Genital/urinary tract infection | 35 (17.5) | 6 (14.3) | 29 (18.4) | > 0.20 |
Pneumonia | 20 (10) | 4 (9.5) | 16 (10.1) | > 0.20 |
Intra-abdominal infection | 16 (8) | 3 (7.1) | 13 (8.2) | > 0.20 |
Bacteremia of unknown source | 9 (4.5) | 2 (4.8) | 7 (4.4) | > 0.20 |
Prosthetic joint infection | 6 (3) | 1 (2.4) | 5 (3.2) | > 0.20 |
Endocarditis | 5 (2.5) | 2 (4.8) | 3 (1.9) | > 0.20 |
CNS infection | 4 (2) | 0 (0) | 4 (2.5) | > 0.20 |
Additional oral antimicrobials | 56 (28) | 15 (35.7) | 41 (25.9) | > 0.20 |
Total number of IV antimicrobials [median (IQR)] | 1 (1–1) | 1 (1–1) | 1 (1–1) | > 0.20 |
Total number of all antimicrobials [median (IQR)] | 1 (1–2) | 1 (1–2) | 1 (1–2) | > 0.20 |
Duration of IV antimicrobial therapy, including inpatient (days) [median (IQR)] | 35.5 (15–43) | 42 (18–46) | 30 (14–43) | 0.03 |
Planned duration of OPAT (days) [median (IQR)] | 18 (7–34) | 23 (9–34) | 16 (7–33.5) | > 0.20 |
PICC line | 155 (77.5) | 36 (85.7) | 119 (75.3) | 0.15 |